The biosimilars sector is predicted to be worth $19.4bn (€13.6bn) by 2014, by which time the US will have overtaken Asia as the dominant market, according to a report.
The EMEA has issued US biotech firm Genzyme with a letter detailing “one major observation and several other observations” following an inspection of its Allston, Massachusetts manufacturing plant last month.
In the next week the Chinese SFDA is expected to approve licences for two locally produced H1N1 vaccines, which unlike some alternatives only require one dose to confer immunity.
Sanofi-aventis is initiating the phased closing its manufacturing facility in Kansas, US, with complete shutdown expected to occur in 2012 and impact on 370 employees.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Laxai, LabConnect, ERT and Avid Bioservices.
Drug development partnering site goBalto’s addition of Latin American clinical sites to its database in a deal with Chilean CRO Clinical Trials Support (CTS) is timely given the pharma and biotech industry’s focus on emerging markets.
Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Novartis’ former CEO joining Amylin’s board and an appointment at OctoPlus.
US software group SourceSolution has signed a co-marketing deal with bioProcessUK they claim will help UK pharma contractors raise their global profiles and find new drug industry clients.
Europe is pulling ahead of the US in research productivity, according to a controversial new study by Washington public policy think tank Health Affairs.
Pfizer’s new $214.8 million (€150m) biotechnology facility in Strangnas, Sweden was inaugurated yesterday, securing the country’s future in the company’s manufacturing network according to global manufacturing president Natale Ricciardi.
Indian CRO Siro Clinpharm has set its sights on the European research market, signing a deal with UK based CambReg that it hopes will offer customers a path through the region’s complex regulations.
The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important role, according to a new survey by industry analysts RNCOS.
UK drug major GSK says that two lots of its respiratory drug Advair Diskus have been stolen from a distribution facility in Richmond, Virginia in the US.
Woman’s healthcare and dermatology group Warner Chilcott will unveil plans to buy P&G’s prescription drug division for $3bn (€2.1bn) according to a number of media reports.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
Outsourcing-Pharma presents its latest round-up of movements in the pharmaceutical outsourcing sector, including appointments at AAIPharma, NextPharma and Catalent.
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has ordered the recall of 100 batches of drugs sold by generics firm Karib Kem Pharm.
US drug giant Pfizer has joined the growing list of organisations seeking to boost trial recruitment via the web, teaming up with IT firm Private Access to create a website designed to “increase clinical trial awareness and participation.”
inVentiv Health is expanding it REMS-related services, which it believes is a growth area, using its experience in risk management to help clients formulate strategies.
India-based CRO Vimta Labs is aiming to lower the cost of diagnostic services by developing new panels using MassTag PCR technology licensed from Columbia University, New York.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Millipore, AM Technology and Alder Pharmaceuticals.
Gilead Sciences is laying off up to 66 people as it closes its offices in Boulder and Westminster, Colorado, US to consolidate its operations in California.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including mass director resignations at Gentium and executive lay-offs at Ambrilia.
Outsourcing-Pharma presents its latest round of movements in the pharmaceutical outsourcing sector, including appointments at inVentiv and GVK Biosciences.
France will lead growth in the European API market, according to a new report that believes the government’s cost-containment measures will put increased focus on the nation’s generic sector.
Nigeria is collaborating with Interpol and setting up offices in India to curb the flow of counterfeits, in particular allegedly China produced fakes labelled “Made in India”, according to media reports.
in-PharmaTechnologist presents its latest round-up of movements in the pharmaceutical sector, including a new CEO at Caraco, appointments at Mylan and the return of the “Viking boss”.
In the latest twist in an increasing bitter takeover battle, the Ontario Superior Court of Justice has rejected JLL’s bid to oust directors elected to the board of Canadian CMO Patheon in April.
The financial impact of Caraco’s cGMP compliance issues have been revealed in its Q1 results, which saw a $14m (€9.9m) operating income in 2008 turn into a $14m loss this year.
KV Pharmaceutical has hired a firm specialising in restructuring and bankruptcy and said “there are significant uncertainties regarding its ability to continue as a going concern during the upcoming fiscal year”.
The EMEA is fast tracking the review of data on H1N1 pandemic vaccines to ensure it has checked submissions before the northern hemisphere flu season, which starts in September.
Sanofi-Aventis is continuing to expand in emerging markets by agreeing to acquire Indian vaccine manufacturer Shantha Biotechnics in a deal that values the company at €550m ($784m).
Rumours suggest that US drug giant Pfizer is considering a bid for Turkish generics group Abdi Ibrahim as part of its strategy of expanding in emerging markets.
The US consumer healthcare products division of GlaxoSmithKline (GSK) has hired Informance International to implement overall equipment effectiveness (OEE) analysis at its facilities in Clifton, New Jersey and Aiken, South Carolina.
US drugmaker Oscient Pharmaceuticals has filed for chapter 11 bankruptcy and will sell its bronchitis therapy Factive (gemifloxacin mesylate) to North Carolina-based Cornerstone Therapeutics for $5m (€3.5m).
Swiss firm Roche has begun making cuts at recent $46.8bn biotech acquisition Genentech, in the first stage of a widely anticipated integration programme.
Indian generics firm Ranbaxy voluntarily withdrew one batch of its acne drug isotretinoin from US shelves late last week after FDA analysis revealed out of spec dissolution test results.